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BACKGROUND
Chemoresistance poses a large clinical challenge to 
successfully treating cancers like breast, ovarian, and 
lymphoma. Chemotherapies put tremendous selective 
pressures on cancers, resulting in many possible 
modalities to establish resistance (Gottesman, 2002). 
Importantly, cancers do not need to acquire a permanent 
resistance phenotype to effectively combat 
chemotherapies (Yague, 2003). Transporters, including 
both the ATP-binding cassette (ABC) and solute carrier 
(SLC) superfamilies, represent one important method
METHODS
Immunohistochemistry performed on clinically derived canine lymphomas to determine if 
SLC transporters could represent a clinically relevant target;
Four chemo-naïve canine lymphoma cell lines (Oswald, 1771, CLBL1, and CLL1390) were 
selected for downstream in vivo assays;
Cell toxicity assays were performed to determine the IC50 values for each of the CHOP 
protocol drugs;
CHOP; C-cyclophosphamide, H-hydroxydaunorubicin (doxorubicin), O-oncovin
(vincristin), P-prednisolone
qRT-PCR, ChIP-targeting acetylated histones, and COBRA (targeting methylated DNA) will 
be used to correlate transporter gene expression, changes in epigenetic modulation, and 
the establishment of a resistance phenotype after short and long-term combination drug 
exposure
RESULTS 3: IC50 Determination for Oswald and 1771RESULTS 1: SLC Transporters are differentially expressed in 
canine lymphomas
Lymphoma Type OCT1 OCT3 OAT3
Large B-cell + + +
Small B-cell + + +
T-cell + + -
Lymphoblastic + - -
Lymphoblastic - - -
Centroblastic - - -






Figure 1. Representative images from IHC against listed antibodies in three of the six 
clinical lymphoma samples. Table 1. IHC results were tabulated according to clinical 
sample, highlighting a pattern of differential expression.
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DISCUSSION
IHC data reveals SLC transporters are differentially expressed in canine clinical
lymphoma samples. These data suggest that SLC expression (and translation) can be
dynamic amongst a sample population of chemo-exposed lymphomas. This provides a
proof-of-concept for the study, and the need for further insight into temporal changes in
transporter expression. IC50 value determination now permits us to begin the next step
of the project: monitoring of transporter gene expression and epigenetic modulations,
but only for three of the four CHOP drugs. Dose response curves for cyclophosphamide,
an alkylating agent, have not been generated due to complications with the dosing
strategy. Additionally, curves for prednisolone could not be generated due to the lack of
cytotoxicity of the drug, which was dosed beyond the clinically relevant equivalent.
Cells will be maintained in either short- or long-term treatment regimens of different
combinations of the CHOP protocol. Gene expression will be evaluated by qRT-PCR
targeting transporter mRNA and splice variants. These data will begin to reveal temporal
changes in transporter expression, and according to hypothesis, will correlate with the
extent of treatment that each cell line receives.
Drug Oswald 1771
Doxorubicin 7.7 ng/mL 211.3 ng/mL
Vincristine 31.2 ng/mL <0.73 ng/mL
Prednisolone >10 ug/mL >10 ug/mL
Table 3
Figure 3. Dose response curves for Oswald and 1771 cell lines. Curves for 
prednisolone and vincristine (1771) were omitted. Table 3. Tabulated data of 
calculated IC50 values from cytotoxicity assays.
Figure 3
In both human and veterinary oncology, multi-drug
resistance (MDR) is a phenomenon where a cancer gains a
cytoprotective effect against chemotherapeutics. Resistance
is often witnessed when remitted cancers relapse and
become untreatable. As an example, canine lymphomas are
notorious for relapsing after treatment with the multi-drug
CHOP protocol and response rates for a second remission are
substantially lower. While canonical drug efflux transporters
have been implicated in the MDR phenotype, other transporters shown to import cytotoxic
drugs might also contribute. Recent research has demonstrated that exposure to some
chemotherapeutics can result in epigenetic changes to transporter gene expression; this
could be a possible route for acquiring a resistance phenotype. What is still unknown,
however, is a mechanistic understanding of the chemotherapy-transporter expression
relationship. To address this void, we are focusing our research on three questions
1. What are the temporal fluctuations in transporter expression following exposure of 
canine    lymphoma cells to multi-drug regimens?
2. What patterns of epigenetic markers on transporter genes promote altered 
expression?
3. How does transporter mRNA expression correlate to protein levels in chemo-resistant 
lymphomas?
We will address each of the questions using genomic and pharmacokinetic methods. This
research will provide new mechanistic understandings of chemoresistance, which has useful
translational implications.
cancers can use to establish permanent and transient resistance because of the wide 
variety of transporters to choose from and their transient expression on cell membranes. 
Some of the key ABC and SLC transporters have been characterized biochemically, but not 
much is known about the distribution of these proteins in a membrane, or the regulatory 
factors that control their expression. It is hypothesized that cancers exploit a combination 
of these two transporter families to establish and maintain the MDR phenotype.




Figure 2. Representative images from fluorescent image capture of Oswald (labeled 
with nuclear-red protein) during 42 hour cytotoxicity assay.
